Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227896 · ClinicalTrials.gov registry record
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
A clinical trial, sponsored by AbbVie.
- Not yet
- Registry status
- 100
- Enrollment target
NCT07227896 is a clinical trial that has not yet begun recruiting, run by AbbVie. The registered enrollment target is 100 participants.
The verdict
NCT07227896 has not yet begun recruiting, sponsored by AbbVie.
- NOT YET RECRUITING
- Registry status
- 100 participants
- Enrollment target
Study Summary
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world. Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months. There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2027-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227896
The ClinicalTrials.gov registry entry for NCT07227896 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07227896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07227896 about?
NCT07227896 is a clinical study titled "Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease". Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidop...
What is the current status of trial NCT07227896?
This trial is currently not yet recruiting. The enrollment target is 100 participants. The study started on 2026-03-01. Estimated completion is 2027-10.
Who is sponsoring clinical trial NCT07227896?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.